ERBB2 and breast cancer: To confirm that the above-described mechanism controls ABCC gene expression in other cancer types, which are also eligible for cisplatin-based chemotherapy, we tested the triple-negative (progesterone, estrogen, and HER2 deficient; TNBC) breast cancer cell line MDA-MB-231 in a similar experimental model.